Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Treatment of Severe Hives (Urticaria)

Introduction to Treatment

  • The American College of Physicians recommends a stepwise algorithm for treating severe hives, starting with high-dose second-generation H1 antihistamines, progressing to omalizumab for refractory cases, and considering cyclosporine as third-line therapy 1

First-Line Treatment

  • Second-generation non-sedating H1 antihistamines are the mainstay of therapy for severe urticaria, with options including cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and mizolastine 1
  • For severe cases, the dose can be increased up to 4 times the standard dose when potential benefits outweigh risks, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
  • Patients should be offered at least two different non-sedating antihistamines, as responses and tolerance vary between individuals, according to the American College of Allergy, Asthma, and Immunology 1
  • First-generation antihistamines should generally be avoided due to sedation and potential to convert minor reactions into hemodynamically significant events, as stated by the American Society of Hematology 3

Second-Line Treatment

  • For severe urticaria unresponsive to high-dose antihistamines, omalizumab is recommended, with a standard starting dose of 300 mg every 4 weeks, as suggested by the American Academy of Dermatology 1
  • Allow up to 6 months for patients to respond to omalizumab before considering alternative treatments, according to the American College of Allergy, Asthma, and Immunology 1
  • Omalizumab is particularly effective for recurrent anaphylaxis and skin symptoms associated with severe urticaria, as reported by the National Comprehensive Cancer Network 4

Third-Line Treatment

  • Cyclosporine is recommended for patients who do not respond to high-dose antihistamines and omalizumab, with an effective rate of about two-thirds of patients with severe autoimmune urticaria at 4 mg/kg daily for up to 2 months, as stated by the British Association of Dermatologists 5, 1
  • Regular monitoring of blood pressure and renal function is required due to potential side effects, as recommended by the American College of Physicians 1

Adjunctive Treatments

  • Short courses of systemic corticosteroids may be used until hives resolve to grade 1 for severe cases, as suggested by the American Academy of Allergy, Asthma, and Immunology 2
  • Cooling antipruritic lotions can provide symptomatic relief, according to the American College of Allergy, Asthma, and Immunology 1, 2

Management of Anaphylaxis

  • For severe urticaria with signs of anaphylaxis, epinephrine is the first-line treatment, as recommended by the National Comprehensive Cancer Network 4
  • After epinephrine administration, antihistamines and corticosteroids can be added as required, according to the American College of Allergy, Asthma, and Immunology 4

Special Considerations

  • Identify and minimize aggravating factors such as overheating, stress, alcohol, and certain medications, as recommended by the American College of Physicians 1, 2
  • NSAIDs should be avoided in aspirin-sensitive patients with urticaria, and ACE inhibitors should be avoided in patients with angioedema without weals, as stated by the American College of Allergy, Asthma, and Immunology 1
  • For patients with renal impairment, avoid certain medications and halve the dose of others, as suggested by the American College of Physicians 1
  • For patients with hepatic impairment, avoid certain medications and adjust doses accordingly, according to the American Association for the Study of Liver Diseases 1

REFERENCES

1

Urticaria Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Acute Urticaria Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

systemic mastocytosis, version 2.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2018